Atlas Trials

Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Clinical trial NCT05300282 · RECRUITING

Trial details

NCT number
NCT05300282
Sponsor
Fondazione Italiana Linfomi - ETS
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory Hodgkin's Lymphoma
Start date
2023-02-27
Primary completion
2027-04-27
Enrollment
122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.